



Partnerships with Bayer

TARGETING CVD

Patient access to CVD services in primary care

- Currently patients are facing considerable challenges accessing primary care services in England, resulting in public dissatisfaction with the NHS. The 2021 GP Patient Survey highlighted that $\geq 1/3$ of survey respondents were unable to obtain a timely appointment. The 2023/2024 ACC-08 IIF indicator addresses this challenge by rewarding PCNs for increases in the percentage of patients with a time from booking to appointment of ≤ 2 weeks¹



NHS Long Term Plan and CVDPrevent

- Prevention is the fundamental goal of the **NHS Long Term Plan**, which endeavours to prevent up to 150,000 heart attacks and strokes across a ten year period²
- “CVD is the single biggest area where the NHS can save lives over the next 10 years.”³
- **CVDPREVENT**, the national primary care audit recognises **AF as one of the ‘six-high risk conditions’** that can predispose to development of CVD²
- It is estimated that there are 425,000 people living with undiagnosed and untreated AF in England,⁴ which presents a dangerous risk of stroke
- **AF is a recognised QOF clinical indicator**⁵



Addressing AF Detect, Protect, Perfect

- Improving patient access to primary care provides an opportunity to make clinically meaningful interventions and address the goal of the NHS Long Term Plan to improve early detection and treatment of CVD³
- Detect, Protect and Perfect is a national programme, aimed at tackling the burden of AF-related strokes⁶
 - o Detect: improve detection of AF through:
 - **Opportunistic screening of at-risk groups through pulse checks incorporated during routine clinical appointments**
 - o Protect: reduce the risk of AF-related stroke by:
 - **Promptly initiating effective anticoagulation**
 - o Perfect: Optimise anticoagulation by:
 - **Individualising treatment to the patient and considering patient preference**⁷



Bayer and the NHS

- Bayer is committed to collaborating and working in partnership with the NHS, to improve outcomes for patients and the healthcare system
- With our vast experience across CVD, we can support the NHS to deliver on the ambitions of the NHS Long Term Plan through our joint working projects covering:
 - o Service improvement
 - o Quality improvement
 - o Provision and interpretation of QOF data
 - o Support to identify priority areas for improvement



AF, atrial fibrillation; CVD, cardiovascular disease; GP, general practice; IIF, Investment and Impact Fund; NHS, National Health Service; PCNs, primary care networks; QOF, Quality and Outcomes Framework.

References

1. NHS England. Network Contract Directed Enhanced Service: Investment and Impact Fund 2023/24: Guidance. April 2023. Available at: <https://www.england.nhs.uk/wp-content/uploads/2023/03/PRN00157-ncdes-investment-and-impact-fund-2023-24-guidance.pdf>. Accessed December 2024. 2. NHS England. CVD PREVENT. Available at: <https://www.england.nhs.uk/ourwork/clinical-policy/cvd/cvdprevent/>. Accessed December 2024. 3. NHS. The NHS Long Term Plan. January 2019. Available at: <https://www.longtermplan.nhs.uk/wp-content/uploads/2019/08/nhs-long-term-plan-version-1.2.pdf>. Accessed December 2024. 4. Routen A. et al. J Public Health (Oxf). 2022 Feb 14;45(1):57-65. 5. NHS England. Quality and outcomes framework guidance for 2024/25. Available at: <https://www.england.nhs.uk/publication/quality-and-outcomes-framework-guidance-for-2024-25/>. Accessed December 2024. 6. NHS England. Atrial Fibrillation (AF) toolkit Detect, Protect and Perfect: Working together across London to prevent AF related strokes. Available at: <https://www.england.nhs.uk/london/wp-content/uploads/sites/8/2019/07/detect-protect-perfect-london-af-toolkit-062017.pdf>. Accessed December 2024. 7. NICE. Atrial fibrillation: diagnosis and management (NG196). Available at: <https://www.nice.org.uk/guidance/ng196>. Accessed December 2024.

PP-M_RIV-GB-0057, December 2024.

Prescribing information and adverse event reporting information for Xarelto® (Rivaroxaban) is available via the QR code on the right. Either click here or scan the QR code for prescribing information and adverse event reporting information. For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.

